Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH MEDIA
GLOBETECH PUBLISHING LLC

US Pharma CEO Compensation Double That of Europeans

By BiotechDaily International staff writers
Posted on 29 Apr 2013
A new report has found that the CEOs of European pharmaceutical companies continue to receive far less than their US counterparts.

The report, from Bloomberg Industries (New York, NY, USA), found that the median salary for the leading pharmaceutical executives in Europe in 2012 was USD 9.3 million, 46% less than the USD 17.2 million earned by CEOs of U.S.-based pharmaceutical companies. Furthermore, the average pay of USD 13.7 million for large-cap pharmaceutical companies was significantly less than the USD 21.9 million paid to the leaders of industrial companies.

Pfizer (New York, NY, USA) CEO Ian Read topped the list with his 2012 compensation of USD 25.6 million, a 2.5% rise from the previous year. According to Pfizer's proxy statement, 90% of Read's 2012 payout was tied to company performance; he was given USD 1.7 million in salary, USD 6.4 million in stock awards, USD 6.5 million in options, and a USD 3.4 million cash bonus. His total compensation also included a USD 7.1 million change in pension value and nonqualified deferred compensation earnings.

That figure was more than five times greater than the USD 5 million paid to Lars Rebien Sørensen, CEO of Novo Nordisk (Bagsværd, Denmark). Another example involves Novartis (Basel, Switzerland) which had to defend against a backlash when it first proposed paying former Chairman Daniel Vasella a USD 78 million noncompete package when he retired; in February 2013, Novartis backed off the payment to Vasella, and he has since left Switzerland for the US.

“Despite the fact that there’s a lot of noise in Europe on top-management remuneration, we’re actually paying less for management teams, by the look of 2012,” said analyst Sam Fazeli, a London-based analyst for Bloomberg Industries. “US CEOs are paid more; if you want to be competitive, then you’ve got to be competitive.”

Related Links:

Bloomberg Industries
Pfizer
Novo Nordisk



Channels

Genomics/Proteomics

view channel
Image: Cancer cells, left, were pretreated with a drug that blocks the ERK signal, and right, without the pretreatment. Top cells are untreated, while the bottom ones are stimulated (Photo courtesy of the Weizmann Institute of Science).

Prevention of ERK Nuclear Translocation Blocks Cancer Proliferation in Animal Models

A team of cell biologists has shown that the cancer promoting effects of ERK dysregulation can be blocked by low molecular weight drugs that prevent translocation of this kinase from the cells' cytoplasm... Read more

Drug Discovery

view channel
Image: Star-like glial cells in red surround alpha-beta plaques in the cortex of a mouse with a model of Alzheimer\'s disease (Photo courtesy of Strittmatter laboratory/Yale University).

Experimental Cancer Drug Reverses Symptoms in Mouse Model of Alzheimer's Disease

An experimental, but clinically disappointing drug for treatment of cancer has been found to be extremely effective in reversing the symptoms of Alzheimer's disease (AD) in a mouse model.... Read more

Biochemistry

view channel
Image:  Model depiction of a novel cellular mechanism by which regulation of cryptochromes Cry1 and Cry2 enables coordination of a protective transcriptional response to DNA damage caused by genotoxic stress (Photo courtesy of the journal eLife, March 2015, Papp SJ, Huber AL, et al.).

Two Proteins Critical for Circadian Cycles Protect Cells from Mutations

Scientists have discovered that two proteins critical for maintaining healthy day-night cycles also have an unexpected role in DNA repair and protecting cells against genetic mutations that could lead... Read more
 

Events

21 Apr 2015 - 23 Apr 2015
21 Apr 2015 - 23 Apr 2015
Copyright © 2000-2015 Globetech Media. All rights reserved.